GlassScriptPhysician profile
Megan Baker
NPI 1144099102
$1,393.47
in general payments reported to CMS, 2019-2025
21 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,198 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $265.48 | 2024-2025 | Voquezna |
| Abbvie INC. | $255.47 | 2024 | |
| Pfizer INC. | $144.10 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $138.07 | 2024 | Tremfya, Remicade, Stelara |
| Qol Medical, LLC | $105.65 | 2024 | Sucraid |
| Astellas Pharma US INC | $100.58 | 2024 | Veozah |
| Janssen Biotech, INC. | $59.73 | 2024 | Stelara, Tremfya |
| Celgene Corporation | $49.12 | 2024 | Zeposia |
| Madrigal Pharmaceuticals | $26.64 | 2024 | Resmetirom |
| Ardelyx, INC. | $25.13 | 2024 | Ibsrela |
| Novo Nordisk INC | $25.01 | 2025 | Rybelsus, Ozempic |
| Ibsa Pharma INC. | $24.55 | 2025 | Licart, Flector, Tirosint |
| Glaxosmithkline, LLC. | $24.01 | 2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $22.57 | 2024 | Entyvio |
| Lilly USA, LLC | $21.75 | 2025 | Mounjaro, Zepbound |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $20.60 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $20.12 | 2025 | Repatha |
| Dexcom, INC. | $18.88 | 2025 | Dexcom G6 Transmitter |
| Braintree Laboratories, INC. | $16.77 | 2024 | Suflave, Sutab |
| Currax Pharmaceuticals LLC | $15.60 | 2024 | Contrave |
| Intercept Pharmaceuticals, INC. | $13.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.